All posts by medical

UCB Snags Eli Lilly UK Research Site, Plans to Invest 1 Billion Over Five Years for R&D – BioSpace

UCB is investing more than 1 billion (roughly 1.29 billion USD) over five years to expand its research and development (R&D) capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.

The global neurology- and immunology-focused biopharma announced Friday it has signed an agreement to acquire the new campus from Eli Lilly to support the companys cutting-edge research and development, early manufacturing and commercialization of medicines for patients with severe neurological and immunological diseases.

Formerly, the facility was Eli Lillys second-largest research site worldwide. Exactly one year ago, Eli Lilly announced it was closing the doors to its neuroscience-focused Erl Wood research center in Surry. The Indianapolis, IN.-based pharmaceutical company said it planned to do so by the end of 2020, effectively impacting 270 staff members and resulting in possibly 80 redundancies. Approximately a third of the non-laboratory workers at the Eli Lilly site was moved to another nearby location. This news followed some months after the company also announced it was cutting 250 jobs at its 1,400-employee factory in Eastern France for the purposes of modernization.

The new U.K. site will be home to one of the companys three global R&D hubs, in addition to those located in Belgium and the U.S. Following completion of the acquisition, which is expected for November 2020, UCB will perform a complete state-of-the-art refurbishment of the campus before staff at its current U.K. headquarters in Slough, Berkshire, move in.

While UCBs five-year plan to invest 1 billion in the U.K. effort will include the new facility, both UCB and Eli Lilly have yet to disclose the financial details on the acquisition. According to UCB, the five-year, 1 billion investment will also support the addition of 650 high-value jobs in scientific research, translational medicine, clinical development, early manufacturing and commercial roles in the region.

We have a strong track record of discovering medicines in the UK which go on to make a difference to the lives of patients worldwide, said UCB CEO, Jean-Christophe Tellier, in a statement. I am delighted to have signed an agreement to secure this new campus for our U.K. hub, from which our scientists will be able to continue to develop their extensive collaborations with some of the most innovative universities, bio-techs and medical research charities, bringing even greater benefit for patients.

Tellier added, This new UK site will not only support our ambitions for future drug discovery but will be well-placed to enable us to achieve our 2030 global sustainability goals and provides an environment which supports the physical and mental wellbeing of our people essential to helping us thrive.

This isnt the first acquisition under UCBs belt. Earlier this summer, UCB announced the news that it had acquired clinical-stage pharmaceutical company Engage Therapeutics for an upfront cash payment of $125 million. Additional potential milestone payments of up to $145 million were also part of the deal. Engage was in the process of developing alprazolam, a single-use therapeutic for the rapid treatment of active epileptic seizures. The acquisition gave UCB worldwide rights to the therapy, in addition to giving them the power to take over further clinical development, submission, launch and commercialization procedures.

Originally posted here:
UCB Snags Eli Lilly UK Research Site, Plans to Invest 1 Billion Over Five Years for R&D - BioSpace

Virtually Supported Home Peanut Introduction is Viable Option – MD Magazine

With the impact of the coronavirus disease 2019 (COVID-19) lockdown measures continuing to be felt across the US, access to healthcare resources for the management of allergic disease are still limited.And although in-person services may be offered by clinics, concern or fear over exposure to the virus can certainly hinder patient use of such services.

And yet, certain allergic conditions, such as peanut allergies in high-risk infants, require expedited assessments and active management.

A report written by Douglas Mack, MD, Assistant Clinical Professor, Pediatrics, McMaster University, and colleagues detailed the first known use of a virtually supported home peanut introduction in infant patients at risk of developing peanut allergy. The program was conducted earlier this year in April.

Prior to initiation of the virtual program, infants were screened for eligibility in a private-practice allergist setting using the telehealth platform Doxy.me.

Patients were eligible if they had physician-diagnosed severe eczema, physician diagnosed egg allergy, SPT3 mm or 0.35 kU/L without prior ingestion, perceived high-risk by caregiver, or had caregiver anxiety to introduce a particular food.

Excluded from the study were patients with a history of systemic IgE-mediated reaction to the food in questions; had certain underlying conditions, such as uncontrolled asthma, cardiac conditions, respiratory conditions; or used a beta-blocker.

During this first consultation, parents or guardians were informed about the risks and benefits of either prolonging peanut avoidance until the first in-person visit or participating in the virtually-support food introduction process.

If they chose to proceed with the program, then consent was obtained, and they were prescribed an epinephrine autoinjector and rupatadine.

In the next visit with the physicians, caregivers were then informed about the process, possible symptoms, and treatment.

Then they were instructed to prepare peanut putter by dissolving 2 teaspoons of it in 2-3 teaspoons of hot water, then letting it cool.

Caregivers then gradually introduced 2 g of peanut butter every 10-15 minutes over 45 minutes 1 hour.

If any symptoms occurred, the guardian used the telehealth program to contact the physicians for further assessment. If the physicians were unable to be reached, then caregivers were instructed to administer epinephrine and/or antihistamine or contact emergency medical services.

However, if no symptoms occurred, then the physicians would advise ingestion of the food of similar or increased amounts 2-3 per week.

Mack and colleagues referenced recent clinical guidelines that provide a framework for at-home management of anaphylaxis. They suggest that using these guidelines would be necessary in the event of such reactions during the virtually supported food introduction.

Nonetheless, they noted that no reactions were reported during the food introduction process, which they considered to be consistent with the current evidence that anaphylaxis is rare and non-threatening with first ingestion in infancy. Thus, they emphasized that mild reactions can generally be managed with antihistamine and/or observation.

Even before COVID-19, lack of allergist resources presented significant barriers to the introduction of peanut to at-risk patients where there was hesitance, they wrote.

During COVID-19, the need to provide alternative forms of care is heightened. Virtually supported introduction may represent a future option after COVID-19 to improve access for patients who live in remote areas, or otherwise have limited access to allergists, or for clinicians with overburdened clinics.

They acknowledged that the implementation of such a strategy requires formal evaluation of safety, cost-effectiveness, caregiver/physician acceptability, sustainability, and patient satisfaction.

The report, Virtually supported home peanut introduction during COVID-19 for at-risk infants, was published online in The Journal of Allergy and Clinical Immunology: In Practice.

View post:
Virtually Supported Home Peanut Introduction is Viable Option - MD Magazine

argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020 – Stockhouse

October 15, 2020 Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2020 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its third quarter 2020 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.

Dial-in numbers: Please dial in 15 minutes prior to the live call.

Belgium 0800 389 13 France 0805 102 319 Netherlands 0800 949 4506 United Kingdom 0800 279 9489 United States 1 866 270 1533 International 1 412 317 0797

About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan. For more information, visit http://www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ .

For further information, please contact:

Beth DelGiacco, Vice President, Investor Relations (US) +1 518 424 4980 bdelgiacco@argenx.com

Joke Comijn, Director Corporate Communications & Investor Relations (EU) +32 (0)477 77 29 44 +32 (0)9 310 34 19 jcomijn@argenx.com

Read more from the original source:
argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020 - Stockhouse

Allergy Partners Discusses Ways to Differentiate Between Cold, the Flu, or COVID-19 – Benzinga

ASHEVILLE, N.C., Oct. 16, 2020 /PRNewswire-PRWeb/ -- Here is how you can tell the difference In the best of times, it can be hard to tell the difference between symptoms of a cold and the flu. With the COVID-19 pandemic, understanding what these symptoms are versus those of COVID-19 is even more important than ever.

Facts The virus causing COVID-19, called SARS-CoV-2, is part of a family of viruses called Coronaviruses. This is a large family of viruses that cause illnesses ranging from the common cold to more severe respiratory illnesses. Coronaviruses can develop in animals and, through mutation, come to infect humans. SARS-CoV-19 is a mutated coronavirus that emerged in China in late 2019. It can cause severe respiratory illnesses such as pneumonia and can be fatal. Yet, in some people the symptoms can be mild. You should seek immediate medical care for any of the following:

Because cold and flu symptoms can appear like some of the symptoms of COVID-19, it is very important to monitor your symptoms closely. The Centers for Disease Control (CDC) has an interactive symptom tracker you can use to determine if you should seek care for possible COVID-19 infection at: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.

Most importantly, keep in contact with your Allergy Partners physician. Our offices remain open and we are offering Telemedicine services to make sure you and your family remain well during this challenging time. Our experienced allergists are anxious to discuss any questions or concerns you may have about COVID-19 and how we can best manage your health together.

WILLIAM A. MCCANN, M.D. Born and raised outside of Baltimore, Dr. McCann has called North Carolina home since completing medical school. After his pediatrics training at Duke, he practiced general pediatrics for three years in Hendersonville. During this time, he realized that his passion lies in the treatment of allergies and asthma. After a brief sojourn in Augusta, Georgia for allergy and immunology training, he returned to Western North Carolina and joined Allergy Partners.

RICHARD L. WASSERMAN, M.D., PHD. Dr. Wasserman received his medical degree from the Mt. Sinai School of Medicine/University of Texas Southwestern Medical School and completed his Pediatrics Residency at Children's Hospital of Philadelphia. Dr. Wasserman completed fellowship training in Bone Marrow transplantation/Immunology at the Children's Hospital of Philadelphia, Postdoctoral Cancer/Immunology at the University of Texas Southwestern Medical School, and Immunology/Rheumatology at The Rockefeller University.

Allergy Partners, PLLC is the nation's largest single specialty practice with multiple locations across the United States. Our allergists provide evaluation and treatment of following conditions:

Allergic Rhinitis | Asthma | Food Allergies | Eczema Hives | Sinus Problems | Stinging Insect Allergies | Immune Deficiencies | Chronic Cough | Drug Allergies Recurrent Infections | Eosinophilic Esophagitis

SOURCE Allergy Partners

See the original post here:
Allergy Partners Discusses Ways to Differentiate Between Cold, the Flu, or COVID-19 - Benzinga

Research Associate job with UNITED ARAB EMIRATES UNIVERSITY | 229041 – Times Higher Education (THE)

Job Description

We offer a research associate/postdoc position in field of Immunology for highly motivated candidate at the department of Biology, College of science, UAE University. In this project, we would like to elucidate the role of the B cells in chronic allergic skin reactions. Characterization of different immune cells involved in allergic skin reactions will be delineated with particular focus on molecular mechanisms.

Minimum Qualification

A successful applicant should have master degree (PhD in case of postdoc) with strong background in Immunology (A must) along with working knowledge of basic techniques like FACS, cell culture, molecular biology and/or bioinformatics. Applicant should be willing to work with animal models. Excellent communication skills, fluency in English and the ability to work independently and together with a team are highly desired. Applicants with above expertise should ONLY apply. The candidates should send their electronic application as single PDF that should include a brief cover letter describing their research experiences related to above field with motivation, CV, and names of two potential referees

Preferred Qualification

M.Sc Life Sciences with major in Immunology

Expected Skills/Rank/Experience

Special Instructions to Applicant

Division College of Science - (COS)

Department Biology - (COS)

Job Close Date 31-01-2021

Job Category Academic - Research Assistant

Salary Salary is commensurate with experience

Excerpt from:
Research Associate job with UNITED ARAB EMIRATES UNIVERSITY | 229041 - Times Higher Education (THE)

Cell Biology Cloud Computing Market with Potential Impact of Coronavirus (COVID19) & Trends That Will Drive Success in 2020 – The Think Curiouser

This versatile composition of research derivatives pertaining to diverse concurrent developments in the global Cell Biology Cloud Computing market is poised to induce forward-looking perspectives favoring unfaltering growth stance.

The market research report on the global Cell Biology Cloud Computing industry provides a comprehensive study of the various techniques and materials used in the production of Cell Biology Cloud Computing market products. Starting from industry chain analysis to cost structure analysis, the report analyzes multiple aspects, including the production and end-use segments of the Cell Biology Cloud Computing market products. The latest trends in the pharmaceutical industry have been detailed in the report to measure their impact on the production of Cell Biology Cloud Computing market products.

Understand the influence of COVID-19 on the Cell Biology Cloud Computing Market with our analysts monitoring the situation across the globe.

Grab A Free Sample Copy of the Cell Biology Cloud Computing Market Report

Leading key players operating in the global Cell Biology Cloud Computing market are : Accenture, Amazon Web Services, Benchling, Cisco Systems, Dell Emc, IBM, DXC Technology, Oracle, ScaleMatrix, IPERION, NovelBio and among others.

The end users/applications and product categories analysis:

Analysis by Application:Further in the subsequent sections of the report, research analysts have rendered precise judgement regarding the various applications that the Cell Biology Cloud Computing market mediates for superlative end-user benefits.

Analysis by Product Type:This section of the report includes factual details pertaining to the most lucrative segment harnessing revenue maximization.

Regional Outlook for Cell Biology Cloud Computing Market.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert

This report comes along with an added Excel data-sheet suite taking quantitative data from all numeric forecasts presented in the report.

Research Methodology: The Cell Biology Cloud Computing market has been analyzed using an optimum mix of secondary sources and benchmark methodology besides a unique blend of primary insights. The contemporary valuation of the market is an integral part of our market sizing and forecasting methodology. Our industry experts and panel of primary members have helped in compiling appropriate aspects with realistic parametric assessments for a comprehensive study.

Whats in the offering: The report provides in-depth knowledge about the utilization and adoption of Cell Biology Cloud Computing Industries in various applications, types, and regions/countries. Furthermore, the key stakeholders can ascertain the major trends, investments, drivers, vertical players initiatives, government pursuits towards the product acceptance in the upcoming years, and insights of commercial products present in the market.

Executive Summary: This particular section of the report lends appropriate focus on various factors such as growth rate, optimum drivers and restraints, competitors as well as trends that define the competition outline.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted Price

Lastly, the Cell Biology Cloud Computing Market study provides essential information about the major challenges that are going to influence market growth. The report additionally provides overall details about the business opportunities to key stakeholders to expand their business and capture revenues in the precise verticals. The report will help the existing or upcoming companies in this market to examine the various aspects of this domain before investing or expanding their business in the Cell Biology Cloud Computing market.

Contact Us:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/2RtaFUo

Follow me on : https://marketnews-24.blogspot.com/

More:
Cell Biology Cloud Computing Market with Potential Impact of Coronavirus (COVID19) & Trends That Will Drive Success in 2020 - The Think Curiouser

Science professor named recipient of NIH New Innovator Award for cancer research – Observer Online

The National Health Institute (NIH) announced in October plans to give out nearly $251 million in grants over five years to 85 different scientists in their High-Risk, High Reward Research Program. Notre Dames Katharine White was on the list.

White is an assistant professor of chemistry and biology at the University of Notre Dame, as well as a 2007 graduate from Saint Marys, whose innovative research caught the attention of the NIH.

She was awarded the Directors New Innovators Award, a prestigious grant with a particular emphasis on supporting young researchers with big ideas.

The award funds exceptionally creative, early career-investigators, so thats people that propose innovative risk but also high reward research, White said. Its research thats innovative, and risky, but has a huge potential impact in human health and improving human health. Broadly, and in this case, improving the treatment of cancer.

Whites research focuses on comparing the relationship of the pH levels within cancer cells to normal cells.

Our research platform in general is at the interface of chemistry and cell biology. We design new chemical tools to manipulate cell biology, White said. Our focus is on understanding how intracellular pH dynamics [regulate] normal cell biology as well as how dysregulated pH dynamics drive diseases like cancer.

Junior Michael Siroky, who has been working in Whites lab since June 2019, said this research has the potential to find new ways to reverse the effects of cancer growth.

Were very interested in how the dysregulation of pH in cancer cells affects a lot of the hallmarks of cancer, like growth and metastasis and different metabolic adaptations, Siroky said. Were primarily focused on how those changes come about and to some extent like how to reverse them.

There are many smaller projects under the umbrella of Whites area of research. Junior Jessamine Kuehn has been a member of Whites lab since spring 2019 and has been working on one of the sub-projects.

My project was working with a particular mutation thats found in 70% of gliomas, Kuehn said. It was a point mutation that changed an arginine, a really basic amino acid, to a histidine, pH near-neutral amino acid, that could actually function as a molecular switch to change, with small changes in the intracellular pH of the cell, the function of the mutated protein.

With the influx of resources the grant will give her lab, White said she will be abled to dive into new avenues and sub-topics of her research. In particular, White said she would be looking into how heterogeneity drives single-cell migration and metastasis events or how the diversity of shape and function of cancer cells impacts their ability to spread in the body.

Furthermore, Siroky said this grant will give the lab the power to increase the specificity of their results and generate new opportunities to share their findings.

Receiving the NIH grant has been an aim for White since its inception. She said she believes her research is unique from other cancer research because it is the intersection between two areas of study applying the usage of chemical tools to gain a better understanding of cellular behavior.

I think one of the key reasons my work is potentially highly innovative [is] because it exists at this interface between chemistry and cell biology, White said.

Kuehn works closely with White as she learns new skills for the projects she takes on in the lab.

I have a lot of one on one [time], like learning procedures with [White]. Its really nice that shes available for that kind of guidance. I really appreciated that, Kuehn said.

Siroky said he is glad to see Whites hard work pay off.

Its pretty gratifying, especially knowing how hard [White] works inside and outside the lab, Siroky said. Shes always fighting for all of these opportunities; its really good to see one of them thats this important pay off because she definitely deserves it to the fullest extent.

Follow this link:
Science professor named recipient of NIH New Innovator Award for cancer research - Observer Online

The Time-resolved Fluorescence Microscope market to Transcend the Covid-19 Barrier from 2021 onwards – PRnews Leader

Time-resolved Fluorescence Microscope Market: Introduction

Increasing demand for the advanced, efficient, and high-resolution diagnostic tools in the medical and life science industry leads to significant demand for the fluorescence microscopy. Time-resolved fluorescence microscope seems to be a promising diagnostic tool and have rapid and fast analysis ability which can be used in several fields of medical applications. Time-resolved fluorescence microscopes have emerged as the choice of the researcher to analyze biologic systems and cell biology researches. Time-resolved fluorescence microscope is an efficient tool for the analysis of the fluorescence properties of the sample. Time-resolved fluorescence microscope is generally used to measure the fluorescence properties of the sample or molecules. Time-resolved fluorescence microscope is widely used to analyze organic compounds medical laboratories and used for drug screening applications. Time-resolved fluorescence microscopes are gaining demand for map interactions between lipids, proteins, DNA, RNA, enzymes

Time-resolved Fluorescence Microscope Market: Drivers and Restraints

Increasing adoption of the advance and new technologies among researcher has led to the tremendous growth of the time-resolved fluorescence microscope market. Increasing life science-based research to diagnose the various disease are creating significant demand for the time-resolved fluorescence microscope. Advancement of the Time-resolved fluorescence microscope leads to significant demand for the devices among researchers and medical industry manufacturers. The growing number of biopharmaceutical research and drug discovery are the major factor expected to boost up the demand for the time-resolved fluorescence microscope market. Growing demand for time-resolved fluorescence microscope in medical areas such as molecular and cellular biology, proteomics, biochemistry boost up the growth of the time-resolved fluorescence microscope market. However, factors such as the high cost of the devices and less profitability are some of the factors negatively impact the growth of the time-resolved fluorescence microscope market.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/30639

Time-resolved Fluorescence Microscope Market: Segmentation

Tentatively, the global time-resolved fluorescence microscope market can be segmented on the basis of product type, application, end user, and geography.

Based on product type, the global time-resolved fluorescence microscope market is segmented as:

Based on application, the global Time-resolved Fluorescence Microscope market is segmented as:

Based on end users, the global Time-resolved Fluorescence Microscope market is segmented as:

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/30639

Time-resolved Fluorescence Microscope Market: Overview

Since few years time-resolved fluorescence lifetime spectrometry technique applications are continuously growing in the pharmaceutical and biotechnology industry as well as in a laboratory. Time-resolved fluorescence microscopes are used for different applications such as forensic, drug discovery, biologics research, cell biology and biomolecules based researches and more. Moreover, Time-resolved fluorescence microscopes have substantial demand in the academic and research institutes as a growing number of researches and study on the diverse biologic particles.

Time-resolved Fluorescence Microscope Market: Regional Outlook

North America expected to dominate the global time-resolved fluorescence microscope market as high demand for technologically advanced tools for the research purpose. Europe expected to register second higher market value share in global time-resolved fluorescence microscope market as increasing number medical research, molecular and drug discovery. Asia Pacific market expected to register higher opportunities for time-resolved fluorescence microscope market players as increasing healthcare and research funding for medical researches. China, India, South Korea are the major countries in the Asia Pacific market which grow at a faster pace in the medical science and research industry. Japan is the established market for the time-resolved fluorescence microscope market players as high adoption of new technologies in clinical laboratories.

Time-resolved Fluorescence Microscope Market: Key Players

Examples of some of the key players operating in the global time-resolved fluorescence microscope market are Agilent Technologies, Inc, PicoQuanT GmbH, Carl Zeiss AG, Danaher Corporation, Olympus Corporation, Edinburgh Instruments Ltd., HORIBA Scientific, Aurora Biomed Inc., Thermo Fisher Scientific, Malvern Panalytical Ltd. and other companies.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/30639

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Go here to read the rest:
The Time-resolved Fluorescence Microscope market to Transcend the Covid-19 Barrier from 2021 onwards - PRnews Leader

CIRM Bridges to Stem Cell Research & Therapy The Bridge to Everywhere (in biomedicine) OP-ED – The Silicon Valley Voice

In a recent clinical trial for an immune cell therapy for lymphoma, 62% of patients experienced complete cancer clearance in spite of the fact that some of them were on their 5th line of treatment. Stem cell therapies have the potential to enact more of these paradigm-shifting treatments. Proposition 14 will continue to advance these therapies and bring them to full development as available cures.

The vision of stem cell therapy is that a physician can just as easily grab an IV bag full of therapeutic cells as they might draw a drug into a syringe. Conceived through Proposition 71 in 2004, the California Institute for Regenerative Medicine (CIRM) serves as a vehicle to support all aspects of stem cell research. Medical progress requires not just well-designed clinical studies but also a well-trained workforce, educated at the intersection of stem cell biology, engineering, and chemistry.

Since 2008, CIRM has supported the training of nearly 1300 Community College and California State University students for the emerging field of Regenerative Medicine through the Bridges to Stem Cell Research and Therapy Program. The Bridges Training Program has functioned as a pathway for first-generation and underrepresented students from Humboldt to San Diego, to all of the biomedical sectors startup and cell therapy companies, academic research institutes, graduate and medical school, and more. Exposure to hands-on labs, advanced seminar discussions, and a required paid internship fully prepares these students for entering the stem cell workforce. Over 80% of Bridges alumni have either advanced to graduate school or joined the biomedical workforce in industry or academic institutions. These Programs bring a greater return than the initial cost of training.

SPONSORED

Consider Vahid Hamzeinejad, a bright high school student, headed to UC Berkeley to begin his college career. Enter the Great Recession; Vahid found himself back at home, working non-stop to help keep his parents restaurant afloat. Not giving up on his commitment to an education, he enrolled at the College of the Canyons. After completing an Associates degree, Vahid transferred to Cal Poly, hoping to join the Bridges Program. After receiving the Bridges core training, Vahid started his internship at ViaCyte, where he continues to work today, as a critical member of the team supporting ViaCytes clinical development of a functional cure for diabetes. The nearly $30 billion that California currently spends on diabetes treatments could be significantly reduced, in no small part due to the efforts of a student that cost taxpayers $36,000 to educate. That is before considering the benefit to patients quality of life that would occur by replacing insulin pumps, glucose monitors, and constant vigilance with a stem-cell-derived tissue that regulates blood sugar levels biologically making and secreting its own insulin.

Passing Proposition 14 will enable this and other unparalleled treatments for diabetes, heart disease, cancer, and neurological disorders.

Signed,

Robert Kam and the CIRM Bridges Program

SPONSORED

Go here to read the rest:
CIRM Bridges to Stem Cell Research & Therapy The Bridge to Everywhere (in biomedicine) OP-ED - The Silicon Valley Voice

The Nobel Prize – Meet the 4 women of 2020 – Omniscience

And then there were 61.

Apart from Marie Curie being honored twice, the Nobel Prize and Prize in Economic Sciences have been awarded to women 58 times between 1901 and 2020. Heres another way of phrasing it. 6% of the total 962 Nobel Laureates were awarded to women. That said, lets celebrate the women who have made this year worthy of celebration.

Emmanuelle Charpentier

Chemistry

My wish is that this will provide a positive message to the young girls who would like to follow the path of science, and to show them that women in science can also have an impact through the research that they are performing. - 2020 Chemistry Laureate Emmanuelle Charpentier

Biochemist, geneticist and microbiologist, currently director of the Department of Pathogen Science at the Max Planck Institute in Berlin (Germany), Professor Emmanuelle Charpentier was named co-winner of this year's 2020 edition along with Jennifer Doudna. The prize rewards their development of the Crispr/Cas9 technology in 2012 capable of modifying human genes.

This immune defense system of bacterial origin was discovered by Emmanuelle Charpentier. The two laureates then succeeded in recreating in the laboratory these molecular scissors that make it possible to modify the genome of a human, animal, plant or microorganism cell in order to inactivate, correct or replace a gene. This technique has revolutionized research, first in medicine, for the development of gene therapy targeting rare diseases and cancers, and also in agronomy, paving the way for new genetically modifiable seeds.

Emmanuelle is now the seventh woman in the world to receive the Nobel Prize in Chemistry, out of 185 laureates. This honour means she joins Marie Curie and her daughter Irne Joliot-Curie in the short list of women to have won the Nobel Prize in Chemistry.

Jennifer A. Doudna

Chemistry

One of the problems in the biotech world is the lack of women in leadership roles, and I'd like to see that change by walking the walk.- 2020 Chemistry Laureate Jennifer A. Doudna

Professor Jennifer Doudna and Emmanuelle Charpentier are not only the sixth and seventh women to win in this category but also the first two women to jointly win the chemistry prize with their revolutionary work on Crispr-Cas9.

Jennifer Anne Doudna is an American biochemist, molecular biologist and geneticist and Professor and Chair in the Department of Chemistry and the Department of Molecular and Cell Biology at the University of California, Berkeley. Their new find enables researchers to now change the DNA of not only plants and microorganisms but also that of animals with extremely high precision. The contribution of this discovery is set to revolutionise the future of cancer therapies and curing inherited diseases

Louise Glck

Literature

The master said You must write what you see. But what I see does not move me. The master answered Change what you see. - 2020 Literature Laureate Louise Glck

The American poet Louise Glck, 77, won the Nobel Prize for Literature on Thursday.

She was awarded "for her characteristic poetic voice, which with its austere beauty makes individual existence universal," announced the Swedish Academy in awarding the prize. Louise Glck won the Pullitzer Prize for Poetry in 1993 for her collection The Wild Iris.

After a first work entitled Firstborn, the poetess was quickly recognized as one of the most important poets of contemporary American literature. She has published twelve collections and several volumes of essays on poetry. "Her works are characterized by a concern for clarity. Childhood and family life, the close relationship with parents and siblings are themes that have remained central to her," said the Academy. Louise Glck is a professor of English at Yale University.

Glcks poems are about family, childhood, love, death, loss, trauma, isolation, nature, and animals speaking of disillusionment, disenchantment, and changeability of self. She focuses on issues of self in relation to others and to the natural world, and urges us to listen to ourselves, our unheard voices. In her essay Education of the Poet, she writes, The dream of art is not to assert what is already known but to illuminate what has been hidden. As in her poetry she draws heavily on her life events and sees through a deeply personal lens, she is often called an autobiographical or a confessional poet. Regarding this, chairman of the Nobel Committee Anders Olsson has noted: In her poems, the self listens for what is left of its dreams and delusions, and nobody can be harder than she in confronting the illusions of the self. But even if Glck would never deny the significance of the autobiographical background, she is not to be regarded as a confessional poet.

Andrea Ghez

Physics

"I take very seriously the responsibility associated with being the fourth woman to win the Nobel Prize. I hope I can inspire other young women into the field." 2020 Physics Laureate Andrea Ghez

The Nobel Prize in Physics was awarded on Tuesday to Professor Andrea Ghez along with British researcher Roger Penrose and the German Reinhard Genzel and the American for their work on the universes notorious mystery objects: black holes. Andrea Ghez was honored for "the discovery of a supermassive compact object in the center of our galaxy.

Only half a century ago, the very existence of black holes was still controversial. Last year, these gigantic objects, reputed to be invisible, were shown for the first time in a revolutionary image, a sign of the progress made in unlocking their galactic secrets.

Ghez is well deserving of the Nobel Prize, as her contributions to astronomy are clearly impactful. The discovery of the black hole in the center of our Milky Way, known as Sgr A*, has led to numerous studies about the nature of galaxies, black holes, relativity, and more. In her group at UCLA, Ghez and her collaborators are keeping the momentum going; training the next generation of astronomers, continuing their now decades long observations of stars like S0-2, and working on unraveling new and exciting mysteries at the galactic center.

Visit link:
The Nobel Prize - Meet the 4 women of 2020 - Omniscience